Cardiovascular safety profile of dapoxetine during the premarketing evaluation. - Wikidata - awgldk - TriplyDB

Cardiovascular safety profile of dapoxetine during the premarketing evaluation.

Cardiovascular safety profile of dapoxetine during the premarketing evaluation.

http://www.wikidata.org/entity/Q33159832

about

Dapoxetine: a new option in the medical management of premature ejaculation A benefit-risk assessment of dapoxetine in the treatment of premature ejaculation.Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation A neuroendocrine mechanism of co-morbidity of depression-like behavior and myocardial injury in rats.The discovery and development of vandetanib for the treatment of thyroid cancer.The selective serotonin reuptake inhibitor dapoxetine inhibits voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells.Effect of DA-8031, a novel oral compound for premature ejaculation, on male rat sexual behavior.Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells.

P2860

Q24601186-B2E386E9-DEE5-4043-9495-4EAA8255C0A7 Q33161137-CAE86390-275A-4EAD-814D-2A8BA12B5D7D Q34635746-43530C58-7FC6-43AC-9717-7B6E0F8DAD1E Q35097384-6128093F-E20B-4340-8ACA-41BE07518093 Q38168304-15716D9B-A3DF-4659-9F2B-A6A04C4A47BE Q39136575-AB9E4CA9-E7FB-4F90-99C5-AB611E6E5ECD Q44295704-95AE7095-58FD-4F94-95DB-CEEECB59B771 Q51759464-F9C64851-F7D3-40E7-A9D7-F5E55F368E7C

P2860

Cardiovascular safety profile of dapoxetine during the premarketing evaluation.

http://www.wikidata.org/entity/Q33159832

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cardiovascular safety profile of dapoxetine during the premarketing evaluation.

@ast

Cardiovascular safety profile of dapoxetine during the premarketing evaluation.

@en

type

label

Cardiovascular safety profile of dapoxetine during the premarketing evaluation.

@ast

Cardiovascular safety profile of dapoxetine during the premarketing evaluation.

@en

prefLabel

Cardiovascular safety profile of dapoxetine during the premarketing evaluation.

@ast

Cardiovascular safety profile of dapoxetine during the premarketing evaluation.

@en

P1433

Q33159832-21C6C791-1002-437A-8066-1ED100A8CFE8

P1476

Q33159832-BDA254A2-B48F-401B-B968-BE0513CEC167

P2093

Q33159832-408574F1-F6DB-4F1A-87D4-F686377E153A

Q33159832-92FB9081-48BD-41F8-BF0F-89EDCA521346

Q33159832-A6154DFB-9209-4641-9424-00B2D0E78CE7

Q33159832-F9FF364A-3260-49EB-9A0C-3177AD39DC25

P2860

Q33159832-04500721-1290-4418-BDFA-CEBF34B355B3

Q33159832-0F538E8B-FABA-4BE8-ABF4-8293871D3BFB

Q33159832-11C1B8A7-DFD5-4D90-BAF2-D807BA217DAE

Q33159832-23AD66F6-919F-4EDB-8E11-F1AAB25F7762

Q33159832-28C63932-C639-43B5-8561-52F66ED462CC

Q33159832-3B67C2FC-55BA-422E-9DA4-2FA469D6A8D0

Q33159832-3DC1571A-31E8-4E50-80E2-C1D57E690B45

Q33159832-3FAB1AEC-4D66-4CB6-BA63-1F0238E5A614

Q33159832-40E1BDFE-4243-4D92-A3A1-709C02BFB040

Q33159832-4C770468-9FAF-474B-A939-09417314618D

P304

Q33159832-F9B36A80-B2DF-4104-9671-1C6477CE2A7F

P31

Q33159832-C79946BA-1133-4158-9270-A8B666CFF43E

P356

Q33159832-7064F224-444E-47A6-A1A1-11EA6DEB3DBF

P433

Q33159832-C0B9BBBD-AC8A-4F91-A1FD-2FD6D6E7630D

P478

Q33159832-10CC2279-68A1-4F50-AEFF-4A8A22E37275

P577

Q33159832-F728FDD8-33FC-4AB5-A770-4F2081A0BD5A

P5875

Q33159832-96E77C0F-D85F-4034-96BA-8FBCCA62936E

P698

Q33159832-3989B971-0BA4-400E-8B95-429A1FAE7F97

P921

Q33159832-AE351A02-481E-4B5C-934F-06F2F513F2A9

P932

Q33159832-09E938FE-D9BF-4C4F-AF16-B52A75D62810

P356

11587660-000000000-00000

P1433

P1476

Cardiovascular safety profile of dapoxetine during the premarketing evaluation.

@en

P2093

Joseph W Aquilina

http://www.w3.org/2001/XMLSchema#string

Peter M DiBattiste

http://www.w3.org/2001/XMLSchema#string

Peter R Kowey

http://www.w3.org/2001/XMLSchema#string

Ramagopal V Mudumbi

http://www.w3.org/2001/XMLSchema#string

P2860

Treating patients with ventricular ectopic beats

Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.

The potential role of serotonin in the pathogenesis of neurocardiogenic syncope and related autonomic disturbances.

Neurally mediated syncope: pathophysiology and implications for treatment.

Risk factors for syncope in a community-based sample (the Framingham Heart Study).

The elusive pathophysiology of neurally mediated syncope.

Incidence and prognosis of syncope.

Head-up tilt test with clomipramine challenge in vasovagal syndrome--a new tilt testing protocol.

Neurocardiogenic syncope.

Guidelines on management (diagnosis and treatment) of syncope-update 2004. Executive Summary.

P304

1-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11587660-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50407911

http://www.w3.org/2001/XMLSchema#string

P698

21410293

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

3585760

http://www.w3.org/2001/XMLSchema#string